Q2 FY2026 · ended Jun 30, 2026 · Revenue $5.15M, +34.9% YoY · Filed Aug 14, 2026
Vivos Therapeutics, Inc. (VVOS) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $5.2 million and a net loss of $5.5 million. Free cash flow was -$3.6 million. As of Jun 30, 2026 it held $1.8 million in cash and investments and $12.5 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- VVOS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Littleton, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716166
- Former names
- Vivos BioTechnologies, Inc. (until Sep 29, 2017)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5.2M | $5.1M | $3.8M | $6.8M | $3.8M |
| Operating income | -$4.8M | -$6.6M | -$6.4M | -$4.7M | -$4.9M |
| Net income | -$5.5M | -$7.7M | -$6.9M | -$5.4M | -$5.0M |
| Diluted EPS | -$0.31 | -$0.52 | -$0.56 | -$0.49 | -$0.55 |
| Operating cash flow | -$3.1M | -$6.0M | -$3.8M | -$4.2M | -$3.5M |
| Free cash flow | -$3.6M | -$6.0M | -$5.3M | -$4.2M | -$4.3M |
| Total assets | $24.1M | $25.0M | $25.2M | $25.6M | $26.0M |
| Total liabilities | $28.1M | $26.3M | $26.7M | $23.1M | $21.4M |
| Stockholders' equity | -$3.8M | -$1.1M | -$1.5M | $2.5M | $4.6M |
| Cash and investments | $1.8M | $2.1M | $2.0M | $3.1M | $4.4M |
| Total debt | $12.5M | $12.3M | $13.5M | $12.5M | $11.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 21, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Auditor change
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K/A |
Amended current report
Material agreement, Unregistered share sale
|
Sep 8, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 8, 2026 | Aug 31, 2026 |
All 301 Vivos Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.